Novel antibody drug products

Joseph T. DiPiro, Robert G. Hamilton, John P. Wei

Research output: Contribution to journalArticlepeer-review

Abstract

Recent developments in protein and genetic engineering methods have allowed the production of antibody-derived molecules that have important potential as therapeutic agents. Although monoclonal antibodies of murine origin have been used for therapeutic purposes, limitations due to anti-antibody responses and suboptimal effectiveness for some indications, such as tumor cell killing, have led to the development of human monoclonal antibodies, chimeric and complementarity determiningregion grafted antibodies, immunotoxins, and other engineered products. These novel antibodies are being tested for the treatment and prevention of infectious diseases and for the diagnosis and treatment of cancers, as well as for indications considered nontraditional for antibodies (e.g., as antithrombotics or inhibitors of neutrophil adherence). The availability of antibody drug products raises a number of issues for clinicians. Among these are new patterns of adverse effects, immunogenicity (development of anti-antibody response), important questions regarding administration and dosage, and substantial cost implications.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalThe American Journal of Surgery
Volume164
Issue number1
DOIs
StatePublished - Jul 1992
Externally publishedYes

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Novel antibody drug products'. Together they form a unique fingerprint.

Cite this